In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

US FDA Meeting Requested

 
• By Sushmita Panda
  
Cancer Research
Immutep said it will meet with regulators to discuss next steps after strong OS data for combo therapy in 1L HNSCC. (Shutterstock)

More from Clinical Trials

More from Therapy Areas